NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference
Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's Chief Financial & Business Officer, Bart van Rhijn, will participate in a fireside chat on June 5, 2025, at 3:45 PM EDT in New York. The presentation will be accessible via webcast on the company's investor relations website, with a replay available after the event.
Nanobiotix (NASDAQ: NBTX), un'azienda biotecnologica in fase clinica avanzata specializzata in trattamenti oncologici a base di nanoparticelle, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. Il Chief Financial & Business Officer dell'azienda, Bart van Rhijn, prenderà parte a una conversazione informale il 5 giugno 2025 alle 15:45 EDT a New York. La presentazione sarà disponibile in diretta streaming sul sito web per gli investitori dell'azienda, con la possibilità di rivederla anche dopo l'evento.
Nanobiotix (NASDAQ: NBTX), una empresa biotecnológica en etapa clínica avanzada enfocada en tratamientos contra el cáncer basados en nanopartículas, ha anunciado su participación en la próxima Jefferies Global Healthcare Conference. El Director Financiero y de Negocios de la compañía, Bart van Rhijn, participará en una charla informal el 5 de junio de 2025 a las 3:45 PM EDT en Nueva York. La presentación estará disponible vía webcast en el sitio web de relaciones con inversionistas de la compañía, con una repetición accesible después del evento.
Nanobiotix (NASDAQ: NBTX)는 나노입자 기반 암 치료에 중점을 둔 후기 임상 단계 바이오테크 기업으로, 다가오는 Jefferies Global Healthcare Conference에 참여할 예정임을 발표했습니다. 회사의 최고재무및사업책임자(CFBO)인 Bart van Rhijn이 2025년 6월 5일 오후 3시 45분 EDT 뉴욕에서 진행되는 화상 대화에 참여합니다. 발표는 회사 투자자 관계 웹사이트를 통해 웹캐스트로 시청 가능하며, 행사 후 재방송도 제공됩니다.
Nanobiotix (NASDAQ : NBTX), une entreprise biotechnologique en phase clinique avancée spécialisée dans les traitements du cancer à base de nanoparticules, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. Le Directeur financier et commercial de la société, Bart van Rhijn, participera à une discussion informelle le 5 juin 2025 à 15h45 EDT à New York. La présentation sera accessible en webcast sur le site des relations investisseurs de l’entreprise, avec une rediffusion disponible après l’événement.
Nanobiotix (NASDAQ: NBTX), ein Biotechnologieunternehmen in der späten klinischen Phase, das sich auf nanopartikelbasierte Krebstherapien spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference bekannt gegeben. Der Chief Financial & Business Officer des Unternehmens, Bart van Rhijn, wird am 5. Juni 2025 um 15:45 Uhr EDT in New York an einem Gespräch teilnehmen. Die Präsentation wird per Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein, mit einer Wiederholung nach der Veranstaltung.
- None.
- None.
PARIS and CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference:
Jefferies Global Healthcare Conference
Date: Thursday, June 5, 2025
Time: 3:45 pm EDT / 9:45 pm CEST
Location: New York, NY
Presenters: Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix
Webcast link: Click here
The fireside chats will be webcast live from the events page of the Investors section of the Company’s website. The replay of the webcast will be available following the event.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter
Contacts
| Nanobiotix | |
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Ricky Bhajun Director, Investor Relations +33 (0)6 42 05 34 15 investors@nanobiotix.com |
| Media Relations | |
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com |
Attachment
- 2025-05-28 -- NBTX -- Presenting @ Jefferies -- FINAL
FAQ
When is Nanobiotix (NBTX) presenting at the Jefferies Global Healthcare Conference 2025?
Who will represent Nanobiotix (NBTX) at the Jefferies Healthcare Conference 2025?
How can I watch Nanobiotix's (NBTX) presentation at the Jefferies Conference?
What is Nanobiotix's (NBTX) main business focus?
